Moderna's mRNA Flu Vaccine Receives FDA Approval

The U.S. Food and Drug Administration has granted approval to Moderna's mFLUSIVA, marking the first seasonal influenza vaccine to utilize mRNA technology. This vaccine is cleared for use in adults aged 50 to 64 and represents a significant advancement in vaccine development.